The role of CETP inhibition in dyslipidemia

Current Atherosclerosis Reports

Volumn 9, Issue 2, 2007, Pages 125-133

  El Harchaoui, Karim ^a   van der Steeg, Wim A ^b   Stroes, Erik S G ^b   Kastelein, John J P ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JTT 302; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIFESTYLE; LIPID METABOLISM; LIPOPROTEIN METABOLISM; METABOLIC DISORDER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL ESTER TRANSFER PROTEINS; CLINICAL TRIALS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPERTRIGLYCERIDEMIA; MALE; QUINOLINES; SULFHYDRYL COMPOUNDS;

EID: 34548492485     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-007-0008-5     Document Type: Review

References (52)

1. Doggrell SA: Inhibitors of cholesteryl ester transfer protein - a new approach to coronary artery disease. Exp Opin Invest Drugs 2006, 15:99-106.
2. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES: Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005, 45:185-197.
3. Curb JD, Abbott RD, Rodriguez BL, et al.: A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 2004, 45:948-953.
4. Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al.: Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the Prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk Population Study. Circulation 2004, 110:1418-1423.
5. de Grooth GJ, Smilde TJ, van Wissen S, et al.: The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 2004, 173:261-267.
6. de Vries R, Perton FG, Linga-Thie GM, et al.: Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of cetp and triglycerides. Diabetes 2005, 54:3554-3559.
7. Sikorski JA: Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease. J Med Chem 2006, 49:1-22.
8. Nishida HI, Arai H, Nishida T: Cholesterol ester transfer mediated by lipid transfer protein as influenced by changes in the charge characteristics of plasma lipoproteins. J Biol Chem 1993, 268:16352-16360.
9. Le Goff W, Guerin M, Chapman MJ: Pharmacological modulation of cholesteryl ester transfer protein a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther 2004, 101:17-38.
10. Barter PJ, Brewer HB Jr, Chapman MJ, et al.: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:160-167.
11. Borggreve SE, de Vries R, Dullaart RP: Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003, 33:1051-1069.
12. Tato F, Vega GL, Grundy SM: Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients: role of cholesterol-ester transfer protein and lecithin cholesteryl acyl transferase. Arterioscler Thromb Vasc Biol 1997, 17:56-63.
13. Mann CJ, Yen FT, Grant AM, Bihain BE: Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 1991, 88:2059-2066.
14. Kontush A, Chapman MJ: Antiatherogenic small, dense HDL - guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006, 3:144-153.
15. Venkatesan S, Cullen P, Pacy P, et al.: Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb 1993, 13:1110-1118.
16. Tato F, Vega GL, Tall AR, Grundy SM: Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1995, 15:112-120.
17. Vakkilainen J, Jauhiainen M, Ylitalo K, et al.: LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J Lipid Res 2002, 43:598-603.
18. Davidson MH, McKenney JM, Shear CL, Revkin JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol 2006, 48:1774-1781.
19. Arai T, Yamashita S, Hirano K, et al.: Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb 1994, 14:1129-1136.
20. Ebenbichler CF, Laimer M, Kaser S, et al.: Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein profile in morbidly obese women. Arterioscler Thromb Vasc Biol 2002, 22:1465-1469.
21. Sandhofer A, Kaser S, Ritsch A, et al.: Cholesteryl ester transfer protein in metabolic syndrome. Obesity 2006, 14:812-818.
22. Quintao EC, Medina WL, Passarelli M: Reverse cholesterol transport in diabetes mellitus. Diabetes Metab Res Rev 2000, 16:237-250.
23. Passarelli M, Catanozi S, Nakandakare ER, et al.: Plasma lipoproteins from patients with poorly controlled diabetes mellitus and "in vitro" glycation of lipoproteins enhance the transfer rate of cholesteryl ester from HDL to apo-B-containing lipoproteins. Diabetologia 1997, 40:1085-1093.
24. Lahdenpera S, Syvanne M, Kahri J, Taskinen MR: Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia 1996, 39:453-461.
25. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al.: The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004, 256:482-490.
26. Bagdade JD, Ritter MC, Subbaiah PV: Accelerated cholesteryl ester transfer in plasma of patients with hypercholesterolemia. J Clin Invest 1991, 87:1259-1265.
27. Hannuksela M, Marcel YL, Kesaniemi YA, Savolainen MJ: Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res 1992, 33:737-744.
28. Seip RL, Moulin P, Cocke T, et al.: Exercise training decreases plasma cholesteryl ester transfer protein. Arterioscler Thromb 1993, 13:1359-1367.
29. Dullaart RP, Hoogenberg K, Dikkeschei BD, van TA: Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. Arterioscler Thromb 1994, 14:1581-1585.
30. Lewis-Barned NJ, Sutherland WH, Walker RJ, et al.: Plasma cholesterol esterification and transfer, the menopause, and hormone replacement therapy in women. J Clin Endocrinol Metab 1999, 84:3534-3538.
31. Ahnadi CE, Berthezene F, Ponsin G: Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis 1993, 99:219-228.
32. van Wijk JP, Buirma R, van Tol A, et al.: Effects of increasing doses of simvastatin on fasting lipoprotein subfractions, and the effect of high-dose simvastatin on postprandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis. Atherosclerosis 2005, 178:147-155.
33. Le NA, Innis-Whitehouse W, Li X, et al.: Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism 2000, 49:167-177.
34. Guerin M, Lassel TS, Le Goff W, et al.: Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000, 20:189-197.
35. Kassai A, Illyes L, Mirdamadi HZ, et al.: The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin Biochem 2006, In press.
36. Guerin M, Dolphin PJ, Talussot C, et al.: Pravastatin modulates cholesteryl ester transfer from hdl to apob-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995, 15:1359-1368.
37. Bhatnagar D, Durrington PN, Kumar S, et al.: Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes 1995, 44:460-465.
38. Klerkx AH, de Grooth GJ, Zwinderman AH, et al.: Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 2004, 34:21-28.
39. Marschang P, Sandhofer A, Ritsch A, et al.: Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med 2006, 260:151-159.
40. Durrington PN, Mackness MI, Bhatnagar D, et al.: Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 1998, 138:217-225.
41. Guerin M, Bruckert E, Dolphin PJ, et al.: Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL Profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996, 16:763-772.
42. Watts GF, Ji J, Chan DC, et al.: Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. Clin Sci (London) 2006, 111:193-199.
43. Franceschini G, Lovati MR, Manzoni C, et al.: Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction. Atherosclerosis 1995, 114:61-71.
44. Ponsin G, Girardot G, Berthezene F: Mechanism of the gem-fibrozil-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins. Biochem Med Metab Biol 1994, 52:58-64.
45. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al.: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002, 105:2159-2165.
46. Kuivenhoven JA, de Grooth GJ, Kawamura H, et al.: Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005, 95:1085-1088.
47. Bisoendial RJ, Hovingh GK, El HK, et al.: Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol 2005, 25:e133-e134.
48. Clark RW, Sutfin TA, Ruggeri RB, et al.: Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004, 24:490-497.
49. Brousseau ME, Schaefer EJ, Wolfe ML, et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350:1505-1515.
50. McKenney JM, Davidson MH, Shear CL, Revkin JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 2006, 48:1782-1790.
51. Matsuura F, Wang N, Chen W, et al.: HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest 2006, 116:1435-1442.
52. Clark RW: Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors. Curr Opin Pharmacol 2006, 6:162-168.